Key Inclusion Criteria:  Histologically or cytologically confirmed locally advanced (unresectable) or metastatic r/r solid tumors for which no standard therapy is available or for whom standard therapy is considered unsuitable or intolerable. Male or non-pregnant, non-lactating female subjects age ≥18 years. ECOG Performance Status 0~2. Has at least 1 measurable lesion as defined by RECIST 1.1 criteria . Life expectancy of >3 months, in the opinion of the Investigator. Able to take oral medications and willing to record daily adherence to investigational product. Adequate hematologic parameters unless clearly due to the disease under study. Adequate renal and hepatic function Able to understand and willing to sign a written informed consent form.  Key Exclusion Criteria:  History of another malignancy Known symptomatic brain metastases requiring >10 mg/day of prednisolone. Significant cardiovascular disease Known active HBV, HCV, AIDS-related illness. Has received a live vaccine within 30 days History of active autoimmune disorders or ongoing immunosuppressive therapy. Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors or inducers of cytochrome P450 3A (CYP3A) . Prior treatment with hematopoietic progenitor kinase 1 (HPK1) inhibitors.